Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Allergan
25 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
Licensing
AstraZeneca Completes Recovery of Global Rights to Brazikumab from Allergan
PR-M05-20-NI-019
FDA Approval
Allergan Receives FDA Approval for Migraine Treatment
PR-M01-20-NI-001
Collaboration
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders
PR-M11-19-NI-013
M&A
AbbVie Issues Large Bond to Finance Allergan Merger
PAO-M11-19-NI-006
Recall
FDA Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from Market
PR-M07-19-NI-071
M&A
AbbVie to Acquire Allergan for $63 Billion
PR-M06-19-NI-052
FDA Approval
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
PR-M03-19-NI-054
Data
Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.
PR-M03-19-NI-004
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
PR-M01-19-NI-079
R&D
Allergan Establishes R&D Group in Massachusetts
PAO-M01-19-NI-010
FDA Approval
Allergan Bags Another Body Contouring Approval
PAO-M10-18-NI-023
Clinical Study
Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease
PR-M10-18-NI-024
Acquisition
Allergan Makes Neurotoxin Buy with Acquisition of Bonti Inc.
PAO-M09-18-NI-015
Appointment
Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process
PR-M08-18-NI-096
Fast Track
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
PR-M07-18-NI-080
Clinical Trials
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials
PR-M07-18-NI-067
Announcement
Science Exchange Adds Allergan EVP & Chief R&D Officer David Nicholson to Its Board of Directors
PR-M06-18-NI-099
Clinical Data
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant
PR-M06-18-NI-051
Research Collaboration
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
PR-M05-18-NI-093
Drug Delivery
Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting
PR-M04-18-NI-55
Results
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression
PR-M04-18-NI-018
Earnings
Allergan to Report First Quarter 2018 Earnings and Host Conference Call and Webcast
PR-M04-18-NI-012
NDA
FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
PR-M02-18-NI-108
Acquistion
Allergen Acquires Elastagen
PAO-M02-18-NI-012
«
0
2
»